Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SS109 vs Novoseven in hemophilia A/B with inhibitors (PK and on-demand efficacy)
CTR20232471Phase 2Completed
- Sponsor
- Shengsi Biopharmaceutical
- Start
- Aug 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human coagulation factor VIIa Fc fusion protein in hemophilia A, hemophilia B (HB), sponsored by Shengsi Biopharmaceutical. Started Aug 2023; status: completed.
02
Drugs
recombinant human coagulation factor VIIa Fc fusion protein
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20232471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232471.